InvestorsHub Logo
Followers 10
Posts 504
Boards Moderated 0
Alias Born 04/20/2016

Re: None

Thursday, 12/29/2016 8:17:25 PM

Thursday, December 29, 2016 8:17:25 PM

Post# of 232169
Pourhassan is grossly overpaid and should be replaced. Although company president, Nader Pourhassan, does not have the experience, intellect, or temperment to run a clinical stage biophrama company, he is being paid millions of dollars a year to run Cytodyn. The prospects for this company would be greatly enhanced if Pourhassan were to be replaced with someone with the competence and temperment that Pourhassan sorely lacks.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News